[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2

[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 is a radiopharmaceutical imaging agent designed for positron emission tomography (PET) targeting the epithelial-specific integrin $\alpha_v\beta_6$. The drug consists of the 20-amino-acid peptide A20FMDV2, derived from the foot-and-mouth disease virus, which has high affinity and selectivity for $\alpha_v\beta_6$. To optimize pharmacokinetics, the peptide is bi-terminally PEGylated with two PEG28 chains and conjugated to the macrocyclic chelator PCTA for radiolabeling with Copper-64 ($^{64}$Cu). Integrin $\alpha_v\beta_6$ is significantly upregulated in various aggressive cancers, including pancreatic, cervical, and non-small cell lung cancers, while remaining absent in normal adult epithelia, making it a valuable prognostic marker and target for molecular imaging. Preclinical studies indicate that the PCTA-conjugated version exhibits high tumor uptake and stability, although it shows significant renal accumulation.

Other names

64Cu-PCTA-bi-terminally PEGylated A20FMDV2[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2